MDLinxGabapentin’s Cognitive-Risk Signal is Reshaping Prescribing: What It Means for Today’s Clinical Practice

ℹ️ Observational Association Only Evidence

Gabapentin prescribing has increased substantially over the past decade, particularly for neuropathic and chronic pain conditions. Recent observational research identified an association between repeated gabapentin exposure and subsequent cognitive diagnoses, prompting renewed discussion about patient selection and monitoring.

Clinical Considerations

• Six or more gabapentin prescriptions for chronic low back pain were associated with a 29% increased dementia risk.
• The same analysis found an 85% greater risk of mild cognitive impairment among exposed patients.
• Adults aged 18 to 64 years had more than double the observed risk of dementia and mild cognitive impairment.
• Experts emphasized the study was associational and hypothesis-generating, not evidence of causality.

Practice Applications

• Recognize that current evidence reflects association rather than proven cognitive harm.
• Monitor cognitive symptoms in patients receiving long-term gabapentin therapy.
• Consider lowest effective dosing and periodic reassessment of treatment necessity.
• Interpret risk findings alongside pain severity, comorbidities, and available alternatives.